Financial Performance - Revenue for the fiscal year 2021 was $778.639 million, representing a 20.0% increase from $648.732 million in 2020[6] - Gross profit for 2021 was $491.773 million, up 12.8% from $436.032 million in the previous year[6] - The company reported a net loss of $351.295 million for 2021, compared to a loss of $223.348 million in 2020[6] - The company achieved a revenue of $779 million, representing a significant increase of 15.0% year-over-year[18] - The company recorded a net loss of $351.3 million, with a loss attributable to equity holders of $276.5 million[28] - The company recorded revenue of $778.6 million for the year ended December 31, 2021, representing a 20.0% increase compared to 2020[111] Assets and Liabilities - Total assets increased to $4.380529 billion in 2021, up from $2.469133 billion in 2020[10] - Total liabilities rose to $2.163037 billion in 2021, compared to $1.081187 billion in 2020[10] - Cash and cash equivalents increased to $1,754.4 million from $1,002.1 million[83] - Net current assets increased to $1,840.0 million as of December 31, 2021, compared to $960.5 million as of December 31, 2020[85] - Total borrowings of the group increased to $1,024.8 million as of December 31, 2021, from $241.5 million as of December 31, 2020[84] Market Reach and Product Offerings - MicroPort's products are used in over 20,000 hospitals worldwide, showcasing its extensive market reach[12] - The cardiovascular intervention business saw global sales of coronary stents reach 1.22 million units, a remarkable growth of 132.0% year-over-year[18] - The company holds over 6,800 patents globally, indicating a strong focus on innovation and technology development[12] - The company expanded its drug-eluting stent product coverage to approximately 2,900 hospitals, with an additional 610 hospitals covered during the reporting period[31] - The company launched the Prime® 3D printed hip joint system, which utilizes additive manufacturing technology[33] Research and Development - The R&D team is dedicated to continuous innovation, ensuring the development of high-quality medical devices[12] - R&D expenses reached $297.8 million, accounting for 38.2% of revenue[47] - The group has 26 products in the "green channel" for special approval, maintaining the top rank in the medical device industry for seven consecutive years[47] - The company is developing a comprehensive solution for cardiovascular intervention, with multiple innovative products in the pipeline[47] Corporate Governance and Management - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[191] - The board of directors consists of seven members as of December 31, 2021, including one executive director, three non-executive directors, and three independent non-executive directors[195] - The company has established a nomination committee responsible for reviewing the composition of the board and monitoring the appointment/re-election of directors[200] - The management team is committed to maintaining high standards of corporate governance and operational excellence[94][95] Social Responsibility and Community Engagement - MicroPort is committed to social responsibility, viewing community engagement as integral to its business[13] - The company’s "Feiyan Plan" has covered over 1,400 county-level hospitals, assisting nearly 100,000 patients during the reporting period[31] - The company has established an environmental management system to address the impact of its operations on the environment, emphasizing a commitment to sustainable development[113] Financing and Investments - The company raised approximately $689 million through convertible bond financing, with $579 million from the spin-off of the cardiac valve and surgical robot businesses[28] - The company expanded its financing channels through successful listings of subsidiaries on the Hong Kong Stock Exchange[23] - The company has sufficient bank credit facilities to support future capital expenditures through various financing channels[88] Strategic Partnerships and Acquisitions - The company is actively pursuing strategic partnerships and acquisitions to enhance its competitive position in the market[97] - The group fully acquired Hemovent GmbH, with its core product, the ECMO MOBYBOX System, receiving EU CE certification[44] Employee and Workforce - The group has 8,019 employees globally, with 1,715 located overseas, representing 21.4% of the total workforce[55] - As of December 31, 2021, the company employed 8,019 employees, an increase from 7,068 employees as of December 31, 2020, reflecting a growth of approximately 13.5%[119] Risks and Challenges - The company faced significant market risks due to government policies affecting product pricing, which could lead to a reduction in market share and profitability[116] - The company recognizes various financial risks, including credit risk, interest rate risk, liquidity risk, and currency risk, which are detailed in the financial statements[115]
微创医疗(00853) - 2021 - 年度财报